{
  "as_of": "2026-11-14",
  "slug": "hair-loss",
  "title": "掉髮新藥全景：圓禿與雄性禿",
  "title_en": "Hair Loss Drugs: Alopecia Areata and Androgenetic Alopecia",
  "scope": "圓禿（AA）屬免疫疾病，雄性禿（AGA）涉及雄性素訊號；兩種疾病分組顯示，不能用彼此試驗的生髮數據比較。",
  "scope_en": "Alopecia areata (AA) is immune-mediated; androgenetic alopecia (AGA) involves androgen signaling. The two populations are grouped separately and their hair outcomes are not interchangeable.",
  "short_answers": [
    "截至 2026-11-14，禮來 Olumiant、輝瑞 Litfulo 與印度 Sun 的 Leqselvi 均有美國圓禿核准；安宏 AH-001 則屬另一個雄性禿研發梯隊。",
    "禮來於 2026-09-25 公布青少年圓禿試驗：第 36 週 Olumiant 4 mg 組達 SALT≤20 的比例為 42%，安慰劑為 5%。",
    "Nektar 於 2026-11-12 預計 2026 年 12 月啟動 rezpegaldesleukin 圓禿三期；是否啟動及試驗設計，是 JAK 以外路徑的下一關。"
  ],
  "short_answers_en": [
    "As of 2026-11-14, Lilly’s Olumiant, Pfizer’s Litfulo and India’s Sun Pharma Leqselvi had US alopecia areata approvals; AnHorn’s AH-001 belongs to the separate AGA development field.",
    "Lilly reported on 2026-09-25 that 42% on Olumiant 4 mg versus 5% on placebo reached SALT ≤20 at Week 36 in adolescent alopecia areata.",
    "Nektar said on 2026-11-12 that its rezpegaldesleukin AA Phase 3 was planned to begin in December 2026; initiation and design are the next test beyond JAK inhibition."
  ],
  "asia_section": "台灣安宏於 2025-10-30 公告 AH-001 美國一期完成，定位為外用 AR 降解；一期安全性不代表生髮療效。中國開拓於 2024-04-21 公告 GT20029 雄性禿二期達主要終點；該筆標明歷史資料，未推定後續三期已完成。印度 Sun 的 Leqselvi 是已核准圓禿藥，適應症不同。",
  "asia_section_en": "Taiwan’s AnHorn announced US Phase 1 completion for topical AR degrader AH-001 on 2025-10-30; safety findings do not establish hair-growth efficacy. China’s Kintor reported positive AGA Phase 2 results for GT20029 on 2024-04-21; this is dated historical evidence, without an assumed Phase 3 outcome. India’s Sun Pharma has an approved AA drug, a different indication.",
  "selection_inputs": [
    "R03",
    "article:2026-11-10",
    "client:安宏"
  ],
  "assets": [
    {
      "section": "AA",
      "trials": [],
      "date": "2026-09-25",
      "sources": [
        "https://lilly.gcs-web.com/news-releases/news-release-details/fda-approves-lillys-olumiant-baricitinib-pediatric-patients-12",
        "https://pi.lilly.com/us/olumiant-uspi.pdf"
      ],
      "source_ids": [
        "hair-lilly",
        "hair-lilly-label"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "Olumiant／baricitinib",
      "asset_en": "Olumiant / baricitinib",
      "company": "禮來",
      "company_en": "Eli Lilly",
      "country": "美國",
      "country_en": "US",
      "mechanism": "JAK1／2 抑制劑",
      "mechanism_en": "JAK1/2 inhibitor",
      "route": "口服",
      "route_en": "Oral",
      "stage": "美國已核准",
      "stage_en": "US approved",
      "indication": "圓禿；12 歲以上",
      "indication_en": "AA; age 12+",
      "latest": "青少年第 36 週 4 mg 組 SALT≤20 為 42%",
      "latest_en": "Adolescent Week 36 SALT ≤20: 42% with 4 mg"
    },
    {
      "section": "AA",
      "trials": [],
      "date": "2023-06-23",
      "sources": [
        "https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-litfulo"
      ],
      "source_ids": [
        "hair-pfizer"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "Litfulo／ritlecitinib",
      "asset_en": "Litfulo / ritlecitinib",
      "company": "輝瑞",
      "company_en": "Pfizer",
      "country": "美國",
      "country_en": "US",
      "mechanism": "JAK3／TEC 家族抑制劑",
      "mechanism_en": "JAK3 / TEC-family inhibitor",
      "route": "口服",
      "route_en": "Oral",
      "stage": "美國已核准",
      "stage_en": "US approved",
      "indication": "嚴重圓禿；12 歲以上",
      "indication_en": "Severe AA; age 12+",
      "latest": "FDA 核准依據主試驗 718 人",
      "latest_en": "FDA pivotal evidence: 718 patients"
    },
    {
      "section": "AA",
      "trials": [],
      "date": "2024-07-25",
      "sources": [
        "https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-leqselvi"
      ],
      "source_ids": [
        "hair-sun"
      ],
      "asia": true,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "Leqselvi／deuruxolitinib",
      "asset_en": "Leqselvi / deuruxolitinib",
      "company": "太陽製藥",
      "company_en": "Sun Pharma",
      "country": "印度",
      "country_en": "India",
      "mechanism": "JAK 抑制劑",
      "mechanism_en": "JAK inhibitor",
      "route": "口服",
      "route_en": "Oral",
      "stage": "美國已核准",
      "stage_en": "US approved",
      "indication": "成人嚴重圓禿",
      "indication_en": "Adult severe AA",
      "latest": "FDA 原始核准 2024-07-25；核准與商業供貨分開",
      "latest_en": "FDA original approval 2024-07-25; approval is distinct from supply"
    },
    {
      "section": "AA",
      "trials": [],
      "date": "2026-11-12",
      "sources": [
        "https://www.prnewswire.com/news-releases/nektar-therapeutics-announces-third-quarter-2026-financial-results-302938396.html"
      ],
      "source_ids": [
        "hair-nektar"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "rezpegaldesleukin",
      "asset_en": "rezpegaldesleukin",
      "company": "Nektar",
      "company_en": "Nektar",
      "country": "美國",
      "country_en": "US",
      "mechanism": "IL-2／調節型 T 細胞路徑",
      "mechanism_en": "IL-2 / regulatory T-cell pathway",
      "route": "皮下注射",
      "route_en": "Subcutaneous",
      "stage": "圓禿二期後；三期擬啟動",
      "stage_en": "Post-Phase 2 AA; Phase 3 planned",
      "indication": "圓禿",
      "indication_en": "AA",
      "latest": "圓禿三期擬 2026 年 12 月啟動；不混用異位性皮膚炎三期",
      "latest_en": "AA Phase 3 planned December 2026; distinct from AD Phase 3"
    },
    {
      "section": "AGA",
      "trials": [],
      "date": "2025-10-30",
      "sources": [
        "https://www.anhornmed.com/news/ai-design-ah001-protein-degrader-phase1-complete/"
      ],
      "source_ids": [
        "hair-anhorn"
      ],
      "asia": true,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "AH-001",
      "asset_en": "AH-001",
      "company": "安宏醫藥",
      "company_en": "AnHorn Medicines",
      "country": "台灣",
      "country_en": "Taiwan",
      "mechanism": "AR 蛋白降解",
      "mechanism_en": "AR protein degradation",
      "route": "外用",
      "route_en": "Topical",
      "stage": "美國一期完成公告",
      "stage_en": "US Phase 1 completion announced",
      "indication": "雄性禿",
      "indication_en": "AGA",
      "latest": "2025-10-30 公告完成一期；下一步二期療效驗證，日期未公告",
      "latest_en": "Phase 1 completed per 2025-10-30 release; Phase 2 efficacy testing next, no date verified"
    },
    {
      "section": "AGA",
      "trials": [],
      "date": "2024-04-21",
      "sources": [
        "https://en.kintor.com.cn/news_details/1803365125008502784.html"
      ],
      "source_ids": [
        "hair-kintor"
      ],
      "asia": true,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "GT20029",
      "asset_en": "GT20029",
      "company": "開拓藥業",
      "company_en": "Kintor Pharma",
      "country": "中國",
      "country_en": "China",
      "mechanism": "AR 蛋白降解",
      "mechanism_en": "AR protein degradation",
      "route": "外用",
      "route_en": "Topical",
      "stage": "歷史二期結果已公布",
      "stage_en": "Historical Phase 2 results reported",
      "indication": "雄性禿",
      "indication_en": "AGA",
      "latest": "2024-04-21 公告二期達終點；本筆不推定目前最新期別",
      "latest_en": "Positive Phase 2 release dated 2024-04-21; current stage not inferred"
    }
  ],
  "number_checks": [
    [
      "H1",
      "青少年 Olumiant 4 mg 第 36 週 SALT≤20",
      "42%",
      "hair-lilly-label",
      "42"
    ],
    [
      "H2",
      "同試驗安慰劑 SALT≤20",
      "5%",
      "hair-lilly-label",
      "5"
    ],
    [
      "H3",
      "上述終點時間",
      "36 週",
      "hair-lilly-label",
      "Week 36"
    ],
    [
      "H4",
      "Litfulo 主要試驗患者數",
      "718 人",
      "hair-pfizer",
      "718"
    ],
    [
      "H5",
      "Leqselvi FDA 核准日",
      "2024-07-25",
      "hair-sun",
      "July 25, 2024"
    ]
  ],
  "not_listed_unconfirmed": [],
  "not_listed_note": "",
  "not_listed_note_en": "",
  "summary_expected": {
    "total": 6,
    "approved": 3,
    "clinical": 3,
    "phase2_3": 0,
    "discontinued": 0,
    "asia": 3,
    "taiwan": 1
  }
}
